Lumida
/SLDB
⌘K
Solid Biosciences Inc

Solid Biosciences Inc

SLDB
$8.70USD↓-4.08%-0.37 today

MARKET CAP

932.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$9 – $9

52W RANGE

$4
$11

AI Summary

Stalk
Buy NowMedium

SLDB remains structurally bullish across horizons, with a long-term uptrend confirmed by rising 200DMA and higher lows. The medium-term range support at 9.30–9.60 has held on multiple tests, and the recent short-term pullback into the 20EMA/50SMA and ascending trendline offers a favorable entry. Volume contraction on the retracement and a neutral RSI suggest limited selling pressure, while resistance near 10.25–10.50 marks the next upside gate.

  • ↑$377.7M cash reserves fund R&D through mid-2028
  • ↑Phase 3 IMPACT DUCHENNE dosing initiated for SGT-003
  • ↓Pre-revenue status and $54.8M Q2 loss strain liquidity
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Solid Biosciences Inc. (NASDAQ: SLDB) is a biotechnology company focused on developing innovative gene therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). Positioned as a leading player in the gene therapy domain, Solid Biosciences is known for its lead candidate, SGT-003, aimed at treating DMD. The company's strategic focus on advancing its clinical programs through robust research positions it within the emerging landscape of genetic treatments, seeking to address urgent medical needs with high unmet demand.

Bull says

  • ↑$377.7M cash reserves fund R&D through mid-2028
  • ↑Phase 3 IMPACT DUCHENNE dosing initiated for SGT-003
  • ↑BlackRock’s increased stake signals institutional confidence
  • ↑Potential accelerated FDA approval meeting scheduled Q4 2026
  • ↑Positive stock momentum and low short interest support stability
  • ↑High unmet DMD market demand underpins long-term growth

Bear says

  • ↓Pre-revenue status and $54.8M Q2 loss strain liquidity
  • ↓Unfavorable earnings yield and book-to-price hint overvaluation
  • ↓Leverage reliance elevates funding and interest-rate risks
  • ↓High volatility could trigger sharp sell-offs
  • ↓Negative profitability and weak growth metrics persist
  • ↓$200M ATM offering may dilute shares further

Investment themes with SLDB

Most Shorted Stocks↓ -0.45%

Stocks with highest short interest

LITE · FSLY · IRWD

Earnings Call · Q1 2022 · Mgmt. Guidance

Updated 07-16-2026bullish

Transcript signals

Bull points

  • We are very excited about the durability of the data that we're seeing.
  • We have biopsies out for years that are stable or actually increasing, and we have functional outcomes especially looking at some of the physical measurements, respiratory measurements.
  • we had a bunch of internal discussions bars that we needed to cross to get excited about 003. And we crossed them, and we are excited, and we're taking it to the clinic. And we think there's a lot more potential here outside of Duchenne, too.

Bear points

  • That has allowed us to streamline our organization's structure and reduce our headcount by approximately 35%
Read full transcript analysis ›